Company Coeptis Therapeutics Holdings, Inc.

COEP

US19207A1088

Pharmaceuticals

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 10:34:48 2024-05-20 am EDT			5-day change	1st Jan Change
0.34 ^USD	-2.88%		-1.68%	-55.34%

May. 10	Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 26	Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, including Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc. and Coeptis Pharmaceuticals, LLC., is a biopharmaceutical company. The Company owns, acquires, and develops cell therapy technologies for cancer and other diseases. Its product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen chimeric antigen receptor (CAR) T technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms, which the Company is developing with VyGen-Bio and medical researchers at the Karolinska Institute. Its CAR therapy is a treatment for cancer in which a patient's T cells are genetically engineered to recognize cancer cells to target and destroy them.

Number of employees: 6

Managers	Title	Age	Since
David Mehalick CEO	Chief Executive Officer	56	22-10-27
Brian Cogley DFI	Director of Finance/CFO	38	23-05-16
Daniel Yerace COO	Chief Operating Officer	41	22-10-27
Colleen Delaney CTO	Chief Tech/Sci/R&D Officer	57	23-08-29
Christine Sheehy CMP	Compliance Officer	57	22-10-27

Members of the board	Title	Age	Since
Philippe Deschamps BRD	Director/Board Member	62	22-10-27
Christopher Cochran BRD	Director/Board Member	55	22-10-27
Christine Sheehy CMP	Compliance Officer	57	22-10-27
Gene Salkind BRD	Director/Board Member	71	22-10-27
Chris Calise BRD	Director/Board Member	51	22-10-27
David Mehalick CEO	Chief Executive Officer	56	22-10-27
Daniel Yerace COO	Chief Operating Officer	41	22-10-27
Tara Maria DeSilva BRD	Director/Board Member	56	22-10-27

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	37,118,593	25,373,891 ( 68.36 %)	0	68.36 %

Name	Equities	%	Valuation
Armistice Capital LLC 8.396 %	3,030,269	8.396 %	975 747 $
David Mehalick 7.208 %	2,601,311	7.208 %	837 622 $
Biofin Ventures LLC 6.650 %	2,400,000	6.650 %	772 800 $
Bull Horn Holdings Sponsor LLC 5.227 %	1,886,582	5.227 %	607 479 $
Christine Sheehy 2.800 %	1,010,605	2.800 %	325 415 $
Daniel Yerace 2.800 %	1,010,605	2.800 %	325 415 $
Creative Planning LLC 1.787 %	645,104	1.787 %	207 723 $
Chris Calise 1.396 %	503,698	1.396 %	162 191 $
Meteora Capital LLC 1.236 %	446,251	1.236 %	143 693 $
Geode Capital Management LLC 0.5269 %	190,154	0.5269 %	61 230 $

Name	Equities	%	Valuation
Meteora Capital LLC -	1,197,074	-	26 336 $
RiverNorth Capital Management LLC -	150,000	-	3 300 $
Walleye Capital LLC -	109,050	-	2 399 $
Cantor Fitzgerald & Co. -	106,459	-	2 342 $
HRT Financial LLC -	100,115	-	2 203 $
Ionic Capital Management LLC -	93,559	-	2 058 $
Walleye Trading LLC -	72,560	-	1 596 $
SkyView Investment Advisors LLC -	55,122	-	1 213 $
Cowen & Co. LLC -	45,500	-	1 001 $
CSS LLC -	38,848	-	855 $

Coeptis Therapeutics Holdings, Inc.

105 Bradford Road Suite 420

15090, Wexford

http://www.coeptistx.com

address Coeptis Therapeutics Holdings, Inc.(COEP)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.3501

Average target price

Consensus

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
COEPTIS THERAPEUTICS HOLDINGS, INC.	-55.34%	12.64M
ELI LILLY AND COMPANY	+33.76%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-2.90%	372B
MERCK & CO., INC.	+20.45%	332B
ABBVIE INC.	+6.77%	294B
ASTRAZENECA PLC	+14.30%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+9.33%	168B

Other Pharmaceuticals